Characteristics of patients at entry
Characteristic . | Value . |
|---|---|
| No. of patients (no. of enrollments*) | 32 (34) |
| Age, y | |
| Median | 39 |
| Range | 27-51 |
| CD4 cells/mm3 | |
| Median | 306 |
| Range | 33-745 |
| HIV viral load, log10 copies/mL | |
| Median | 2.70 |
| Range | 1.69-5.20 |
| Antiretroviral therapy, no. of patients | |
| HAART | 32 |
| Dual NRTI therapy | 2 |
| TS prognostic category, no. of patients | |
| Good (T0 or S0) | 19 |
| Poor (T1S1) | 15 |
| Extensive tumor (T1) | 27 |
| Advanced HIV disease (S1) | 18 |
| Other characteristics, no. of patients | |
| 150 or fewer CD4 cells/mm3 | 9 |
| Prior opportunistic infection | 12 |
| Resistant HIV† | 9 |
| More than 50 KS lesions | 26 |
| Prior KS therapy, no. of patients | |
| Radiation therapy | 5 |
| Systemic chemotherapy | 21 |
| Investigational therapy | 13 |
Characteristic . | Value . |
|---|---|
| No. of patients (no. of enrollments*) | 32 (34) |
| Age, y | |
| Median | 39 |
| Range | 27-51 |
| CD4 cells/mm3 | |
| Median | 306 |
| Range | 33-745 |
| HIV viral load, log10 copies/mL | |
| Median | 2.70 |
| Range | 1.69-5.20 |
| Antiretroviral therapy, no. of patients | |
| HAART | 32 |
| Dual NRTI therapy | 2 |
| TS prognostic category, no. of patients | |
| Good (T0 or S0) | 19 |
| Poor (T1S1) | 15 |
| Extensive tumor (T1) | 27 |
| Advanced HIV disease (S1) | 18 |
| Other characteristics, no. of patients | |
| 150 or fewer CD4 cells/mm3 | 9 |
| Prior opportunistic infection | 12 |
| Resistant HIV† | 9 |
| More than 50 KS lesions | 26 |
| Prior KS therapy, no. of patients | |
| Radiation therapy | 5 |
| Systemic chemotherapy | 21 |
| Investigational therapy | 13 |
Two patients originally enrolled at 100 ng/kg were re-enrolled at a higher dose. Subsequent analyses refer to the 34 enrollments.
Resistant HIV was defined as an HIV viral load of more than 3.3 log10 copies/mL in a patient who had received multiple HIV regimens and was currently on an anti-HIV regimen.